合富中国：2025年预亏2500万元到3600万元

Core Viewpoint - Company expects a net loss attributable to shareholders of 25 million to 36 million yuan for the year 2025, compared to a net profit of 27.5663 million yuan in the same period last year, indicating a significant downturn due to changes in the macro environment and industry policies [1] Group 1: Financial Performance - The anticipated net loss for 2025 reflects the impact of changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry, which have led to a reshaping of the market competition landscape [1] - The company's sales revenue and gross profit levels are facing temporary challenges due to fluctuations in product procurement prices from hospital clients and variations in order volumes compared to the previous year [1] Group 2: Strategic Developments - The company has signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital, committing to supply in-vitro diagnostic reagents and consumables, along with comprehensive services [1] - The total procurement amount from Mingji Hospital is expected to be no less than 600 million yuan over a period of 96 months, which, if executed successfully, is projected to have a positive impact on the company's performance in 2026 and subsequent years [1]